Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC) (OPTIMA)
A Phase III, Randomized, Double Blind, Dummy-Controlled Study of ThermoDox® (Lyso-Thermosensitive Liposomal Doxorubicin-LTLD) in Hepatocellular Carcinoma (HCC) Using Standardized Radiofrequency Ablation (RFA) Treatment Time ≥ 45 Minutes for Solitary Lesions ≥ 3 cm to ≤ 7 cm
Sponsor: Imunon
Listed as NCT02112656, this PHASE3 trial focuses on Hepatocellular Carcinoma and remains completed. Sponsored by Imunon, it has been updated 13 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 8 earlier versions
-
Jan 2021 — Nov 2022 [monthly]
Completed PHASE3
-
Nov 2018 — Jan 2021 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Aug 2018 — Nov 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Jul 2017 — Mar 2018 [monthly]
Recruiting PHASE3
-
Feb 2017 — Jul 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Jun 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Imunon
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bangkok, Thailand , Beijing, China , Busan, South Korea , Chengdu, China , Chiang Mai, Thailand , Daegu, South Korea , Dalian, China , Frankfurt, Germany , Fuzhou, China , Guangdong, China and 38 more locations